- Home
- AVIR vs GNFT Comparison
AVIR vs GNFT Comparison
Compare AVIR & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVIR
- GNFT
- Stock Information
- Founded
- AVIR 2012
- GNFT 1999
- Country
- AVIR United States
- GNFT France
- Employees
- AVIR N/A
- GNFT N/A
- Industry
- AVIR Medicinal Chemicals and Botanical Products
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AVIR Health Care
- GNFT Health Care
- Exchange
- AVIR Nasdaq
- GNFT Nasdaq
- Market Cap
- AVIR 273.0M
- GNFT 186.3M
- IPO Year
- AVIR 2020
- GNFT 2019
- Fundamental
- Price
- AVIR $3.68
- GNFT $3.60
- Analyst Decision
- AVIR Hold
- GNFT Strong Buy
- Analyst Count
- AVIR 1
- GNFT 1
- Target Price
- AVIR $6.00
- GNFT $13.00
- AVG Volume (30 Days)
- AVIR 403.3K
- GNFT 4.2K
- Earning Date
- AVIR 08-06-2025
- GNFT 04-24-2025
- Dividend Yield
- AVIR N/A
- GNFT N/A
- EPS Growth
- AVIR N/A
- GNFT N/A
- EPS
- AVIR N/A
- GNFT 0.03
- Revenue
- AVIR N/A
- GNFT $73,187,701.00
- Revenue This Year
- AVIR N/A
- GNFT $15.98
- Revenue Next Year
- AVIR N/A
- GNFT N/A
- P/E Ratio
- AVIR N/A
- GNFT $120.92
- Revenue Growth
- AVIR N/A
- GNFT 105.01
- 52 Week Low
- AVIR $2.46
- GNFT $2.55
- 52 Week High
- AVIR $4.15
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- AVIR 70.64
- GNFT 39.32
- Support Level
- AVIR $3.63
- GNFT $3.61
- Resistance Level
- AVIR $3.78
- GNFT $3.95
- Average True Range (ATR)
- AVIR 0.14
- GNFT 0.15
- MACD
- AVIR 0.02
- GNFT -0.02
- Stochastic Oscillator
- AVIR 80.65
- GNFT 8.30
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.